Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lab21 opens syphilis testing pathways to India

This article was originally published in Clinica

Executive Summary

UK diagnostics firm Lab21 has gained its first sales representatives in India after its immunodiagnostic division signed a distribution agreement with Spectral Diagnostics for its syphilis diagnostic test kits. Spectral, which is Inverness Medical Innovations’ distribution arm in India, will supply more than 500,000 of Lab21’s TPHA kits to the Indian Healthcare market over the next 18 months – the contract is worth approximately $1.1m of revenue for Lab21. The Cambridge-based firm said that India was the first of a number of new territories in which it planned to launch over the next twelve months. Financial terms of the deal were not disclosed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041148

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel